耐利福平结核治疗开始时低体重指数与治疗结局:个体参与者数据荟萃分析
该个体参与者数据荟萃分析纳入5148例≥18岁耐利福平结核成人,比较治疗开始时低体重(BMI<18.5 kg/m2)与非低体重者的不良结局风险。低体重者任何不良结局aOR 1.7、死亡aOR 3.1、失败/复发aOR 1.6,且按WHO治疗区域存在显著效应修饰。
要点
- 耐利福平结核治疗开始时低体重者任何不良结局aOR 1.7(95%CI 1.4-1.9)。
- 低体重者死亡aOR 3.1(95%CI 2.4-3.9),失败/复发aOR 1.6(95%CI 1.2-2.0)。
- 按WHO治疗区域存在显著效应修饰;HIV阴性低体重者24个月死亡率14.8%。
核心结论
- 耐利福平结核治疗开始时低BMI与不良治疗结局风险升高相关,尤其是死亡。
- 按WHO治疗区域存在显著效应修饰。
研究设计与样本
- 个体参与者数据荟萃分析,纳入≥18岁、治疗开始时记录BMI的耐利福平结核成人。
- 共纳入5148例患者,其中1702例(33%)治疗开始时低体重。
- 中位年龄37岁(四分位距29至47岁),455例(9%)有HIV。
- 采用 logistic 回归估计调整比值比(aOR)及95%CI,按人口学、临床和治疗相关因素匹配。
- 用似然比检验评估HIV状态及其他变量的效应修饰,并按HIV分层估计治疗期间死亡累积发生率。
主要发现
- 与非低体重者相比,低体重者任何不良结局aOR 1.7(95%CI 1.4-1.9)。
- 与非低体重者相比,低体重者死亡aOR 3.1(95%CI 2.4-3.9)。
- 与非低体重者相比,低体重者失败/复发aOR 1.6(95%CI 1.2-2.0)。
- HIV阴性患者中,24个月死亡率低体重者14.8%(95%CI 12.7%-17.3%)vs 非低体重者5.6%(95%CI 4.5%-7.0%)。
- HIV患者中,24个月死亡率低体重者33.0%(95%CI 25.6%-42.6%)vs 非低体重者20.9%(95%CI 14.1%-27.6%)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The impact of low body mass index (BMI) at initiation of rifampicin-resistant tuberculosis (RR-TB) treatment on outcomes is uncertain. We evaluated the association between BMI at RR-TB treatment initiation and end-of-treatment outcomes. METHODS: We performed an individual participant data meta-analysis of adults aged ≥18 years with RR-TB whose BMI was documented at treatment initiation. We compared odds of any unfavorable treatment outcome, mortality, or failure/recurrence between patients who were underweight (BMI <18.5 kg/m2) and not underweight. Adjusted odds ratios (aORs) and 95% confidence intervals (CIs) were estimated using logistic regression, with matching on demographic, clinical, and treatment-related factors. We evaluated effect modification by human immunodeficiency virus (HIV) status and other variables using likelihood ratio tests. We also estimated cumulative incidence of mortality during treatment stratified by HIV. RESULTS: Overall, 5148 patients were included; 1702 (33%) were underweight at treatment initiation. The median (interquartile range) age was 37 years (29 to 47), and 455 (9%) had HIV. Compared with nonunderweight patients, the aOR among underweight patients was 1.7 (95% CI, 1.4-1.9) for any unfavorable outcome, 3.1 (2.4-3.9) for death, and 1.6 (1.2-2.0) for failure/recurrence. Significant effect modification was found for World Health Organization region of treatment. Among HIV-negative patients, 24-month mortality was 14.8% (95% CI, 12.7%-17.3%) for underweight and 5.6% (4.5%-7.0%) for not underweight patients. Among patients with HIV, corresponding values were 33.0% (25.6%-42.6%) and 20.9% (14.1%-27.6%). CONCLUSIONS: Low BMI at treatment initiation for RR-TB is associated with increased odds of unfavorable treatment outcome, particularly mortality.
引用
- Campbell JR, Chan ED, Falzon D, et al. Low Body Mass Index at Treatment Initiation and Rifampicin-Resistant Tuberculosis Treatment Outcomes: An Individual Participant Data Meta-Analysis. Clin Infect Dis. 2022. PMID: 35476134. doi:10.1093/cid/ciac322
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。